Abstract
Aim: To investigate the clinical value of HDAC4 in coronary heart disease (CHD) patients. Methods: The serum HDAC4 levels were determined by ELISA in 180 CHD patients and 50 healthy controls. Results: HDAC4 was decreased in CHD patients compared with healthy controls (p <0.001). HDAC4 was negatively linked with serum creatinine (p =0.014), low-density lipoprotein cholesterol (p =0.027) and C-reactive protein (p =0.006) in CHD patients. Moreover, HDAC4 was inversely related to TNF-α (p =0.012), IL-1β (p =0.002), IL-6 (p =0.034), IL-17A (p =0.023), VCAM1 (p =0.014) and Gensini score (p =0.001). Unfortunately, neither HDAC4 high (vs low) (p =0.080) nor HDAC4 quartile (p =0.268) estimated major adverse cardiovascular event risk. Conclusion: Circulating HDAC4 levels have disease monitoring value but are less valuable in estimating prognosis in CHD patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call